What's new in trial design: Propensity scores, equivalence, and non-inferiority

Journal of Extra-Corporeal Technology

Volumn 41, Issue 4, 2009, Pages

  Myles, Paul S ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Bias; Confounding; Equivalence; Non inferiority; Pooled endpoints; Propensity; Surgery

Indexed keywords

ARTICLE; BIOASSAY; CLINICAL TRIAL; EPIDEMIOLOGY; METHODOLOGY; OUTCOME ASSESSMENT; PHARMACOKINETICS; STATISTICAL ANALYSIS;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; EPIDEMIOLOGIC RESEARCH DESIGN; OUTCOME ASSESSMENT (HEALTH CARE); THERAPEUTIC EQUIVALENCY;

EID: 77949887707     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials. Lancet. 2001;357:373-80.
2. Myles PS. Large multicentre trials: What should be done in perfusion? J Extra Corpor Technol. 2007;39:274-7.
3. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122:114-20.
4. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: Observational studies. Lancet. 2001;357:455-62.
5. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-63.
6. Adamina M, Guller U, Weber WP, Oertli D. Propensity scores and the surgeon. Br J Surg. 2006;93:389-94.
7. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: A systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007;134:1128-35.
8. Kaul S, Diamond GA. Good enough: A primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62-9.
9. Siegel JP. Equivalence and noninferiority trials. Am Heart J. 2000;139: S166-70.
10. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: Are they supported by the evidence. Ann Intern Med. 2000;132:715-22.
11. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA. 2006;295:1172-4.
12. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of noninferiority: The ximelagatran experience. J Am Coll Cardiol. 2005; 46:1986-95.
13. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: Are they supported by the evidence. Ann Intern Med. 2000;132:715-22.
14. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev. 2007;18: MR000012.
15. Cleophas TJ, Zwinderman AH. Clinical trials: How to assess confounding and why so. Curr Clin Pharmacol. 2007;2:129-33.
16. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32:51-63.
17. Datta M. You cannot exclude the explanation you have not considered. Lancet. 1993;342:345-7.
18. Myers WO, Gersh BJ, Fisher LD, et al. Medical versus early surgical therapy in patients with triple-vessel disease and mild angina pectoris: A CASS registry study of survival. Ann Thorac Surg. 1987;44:471-86.
19. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-65.
20. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in hightransfusion- risk cardiac surgery. Transfusion. 2006;46:327-38.
21. McGrath T, Koch CG, Xu M, et al. Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes. Ann Thorac Surg. 2008;86:543-53.
22. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet. 1999;354: 716-22.
23. Marzocchi A, Manari A, Piovaccari G, et al. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: Results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J. 2008;29:2972-80.
24. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-72.
25. Greilich PE, Jessen ME, Satyanarayana N, et al. The effect of epsilonaminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: A randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg. 2009;109:15-24.
26. Frieman JA, Chalmers TC, Smith H, et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial. N Engl J Med. 1978;299:690-4.
27. Pocock SJ, Ware JH. Translating statistical findings into plain English. Lancet. 2009;373:1926-8. 28. Freemantle N, Calvert M. Composite and surrogate outcomes in randomised controlled trials. BMJ. 2007;334:756-7.
28. Freemantle N, Calvert M. Composite and surrogate outcomes in randomised controlled trials. BMJ. 2007;334:756-7.
29. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: The story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:701-7.
30. Ferreira-Gonzalez I, Permanyer-Miralda G, Domingo-Salvany A, et al. Problems with use of composite end points in cardiovascular trials: Systematic review of randomised controlled trials. BMJ. 2007;334: 786-8.
31. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, et al. Validity of composite end points in clinical trials. BMJ. 2005;330: 594-6.
32. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: Composite end points. J Card Fail. 2005;11:567-75.
33. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): A randomised controlled trial. Lancet. 2008;371: 1839-47.